Inhibiting lysosomal aldolase: a magic bullet for AMPK activation in treating metabolic disease?
David Carling
Inhibiting lysosomal aldolase: a magic bullet for AMPK activation in treating metabolic disease?
[1] |
Steinberg GR , Carling D . Nat Rev Drug Discov 2019; 18: 527- 51.
|
[2] |
Zhang CS , Li M , Wang Y et al. Nat Metab 2022; 4: 1369- 401.
|
[3] |
Zhang CS , Hawley SA , Zong Y et al. Nature 2017; 548: 112- 6.
|
[4] |
Zhang YL , Guo H , Zhang CS et al. Cell Metab 2013; 18: 546- 55.
|
[5] |
Li M , Zhang CS , Feng JW et al. Cell Metab 2019; 30: 508- 24.
|
[6] |
Zong Y , Zhang CS , Li M et al. Cell Res 2019; 29: 460- 73.
|
[7] |
Gluais-Dagorn P , Foretz M , Steinberg GR et al. Hepatol Commun 2022; 6: 101- 19.
|
[8] |
Myers RW , Guan HP , Ehrhart J et al. Science 2017; 357: 507- 11.
|
[9] |
Pollard AE , Martins L , Muckett PJ et al. Nat Metab 2019; 1: 340- 9.
|
[10] |
Apfeld J , O’Connor G , McDonagh T et al. Genes Dev 2004; 18: 3004- 9.
|
/
〈 | 〉 |